Effects of Growth Hormone Therapy on Thyroid Function of Growth Hormone-Deficient Adults with and without Concomitant Thyroxine-Substituted Central Hypothyroidism*
Authors:
- J. O. L. JørgensenJJJ. O. L. Jørgensen
- P. LaurbergPLP. Laurberg
- J. WeekeJWJ. Weeke
- J. S. ChristiansenJCJ. S. Christiansen
- 1 December 1989
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 69 (6) , 1127-1132
Abstract
Administration of human GH to GH-deficient patients has yielded conflicting results concerning its impact on thyroid function, ranging from increased resting metabolic rate to induction of hypothyroidism. However, most studies have been casuistic or uncontrolled and have used pituitary-derived GH of varying purity, often contaminated with TSH. Therefore, we conducted a double blind, placebo-controlled cross-over study of the effect of 4 months of biosynthetic human GH therapy (Norditropin; 2 IU/m2 · day) on thyroid function in GH-deficient adults (8 females and 14 males; mean + SE age, 23.8 + 1.2 yr). One group (I) was euthyroid without T4 substitution (n = 13), whereas the other (group II) received T4 (n = 9). Serum T4 (nanomoles per L) decreased in both groups after GH treatment [group I, 100 + 8 (mean [ SE) vs. 89 + 8 (P < 0.01); group II, 145 + 18 vs. 115 + 10 (P < 0.05)]. Conversely, GH treatment caused an increase in serum T3 (nanomoles per L) in both groups[group I, 1.9 + 0.1 vs. 2.0 + 0.1 (P < 0.1); group II, 1.7 + 0.1 vs. 1.9 + 0.1 (P < 0.05)]. Similar changes were seen in serum free T4 and T3. The serum T3 level during the placebo period of group I was significantly lower than that in an age-matched reference group (P < 0.02). Serum rT3 (nanomoles per L) was low in group I and decreased significantly, as in group II, after GH treatment[group I, 0.26 + 0.02 (placebo) vs. 0.20 + 0.02 (GH; P < 0.01); group II, 0.38 + 0.05 (placebo) vs. 0.29 + 0.02 (GH; P < 0.01)]. Serum TSH decreased in both groups during GH therapy, though not significantly. Serum thyroglobulin was unaltered and did not differ from that in the reference group. In conclusion, our data are consistent with a GH-induced enhancement of peripheral deiodination of T4 to T3. GH thus seems to play an important role, either directly or indirectly, in the regulation of peripheral T4 metabolism. (J Clin Endocrinol Metab69: 1127, 1989)Keywords
This publication has 12 references indexed in Scilit:
- Reduction of Plasma Immunoreactive Somatomedin C during Fasting in Humans*The Journal of Clinical Endocrinology & Metabolism, 1981
- Action of Human Growth Hormone (hGH) on Extrathyroidal Conversion of Thyroxine (T4) to Triiodothyronine (T3) in Children with HypopituitarismPediatric Research, 1981
- Thyroglobulin and Thyroid Hormone Release after Intravenous Administration of Bovine Thyrotropin in Man*The Journal of Clinical Endocrinology & Metabolism, 1980
- Enhanced Peripheral Conversion of Thyroxine to Triiodothyronine During hGH Therapy in GH Deficient ChildrenThe Journal of Clinical Endocrinology & Metabolism, 1977
- EFFECT OF CALORIC RESTRICTION AND DIETARY COMPOSITION ON SERUM T3AND REVERSE T3IN MANThe Journal of Clinical Endocrinology & Metabolism, 1976
- Effect of Human Growth Hormone on Thyroidal Secretion, Radiothyroxine Turnover and Transport in ManThe Journal of Clinical Endocrinology & Metabolism, 1968
- Effect of arginine on serum levels of insulin and growth hormone in obese subjectsMetabolism, 1967
- SODIUM RETENTION WITH HUMAN GROWTH HORMONE AND ITS SUBFRACTIONS*†The Journal of Clinical Endocrinology & Metabolism, 1961
- THE EFFECT OF HUMAN GROWTH HORMONE IN MANEuropean Journal of Endocrinology, 1959
- METABOLIC CHANGES PRODUCED BY HUMAN GROWTH HORMONE (LI) IN A PITUITARY DWARF*The Journal of Clinical Endocrinology & Metabolism, 1959